News brief
In 2025, FT reported that OpenAI-backed AI drug discovery company Chai raised USD 70 million, with investors including Menlo Ventures and Yuri Milner's DST Global Partners. It uses AI to accelerate drug discovery by analyzing large datasets to identify potential candidates.
Connected profiles
Avenir Growth CapitalInvestors ↗CHAICompanies ↗DCVCInvestors ↗DST GlobalInvestors ↗Menlo VenturesInvestors ↗SV AngelInvestors ↗YosemiteInvestors ↗
Explore
Sources · 1Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
- www.ft.com ↗Published Aug 6, 2025
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2025年，据FT报道，OpenAI支持的AI药物发现公司Chai筹集7000万美元，投资方包括Menlo Ventures与Yuri Milner的DST Global Partners。该公司利用AI加速药物发现，通过分析大量数据识别潜在候选药物。